Nurix ended its fiscal year with an estimated, unaudited $609.6 million in cash and investments as of November 30, 2024.* Based on its operating plan, Nurix anticipates that the company will be able to fund its operating activities into the first half of 2027.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics receives U.S. FDA Fast Track designation for NX-5948
- Nurix Therapeutics price target raised to $35 from $30 at H.C. Wainwright
- Nurix Therapeutics initiated with a Buy at BTIG
- Nurix Therapeutics Reports Promising Trial Results for NX-5948
- Nurix Therapeutics holds a pharmaceutical update conference call